ClinicalTrials.gg
CompletedNCT02836249Updated Oct 15, 2024Results posted

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)

A Phase 3 interventional study of TAF and TDF in HBV and Chronic HBV Infection, sponsored by Gilead Sciences. Completed at 25 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Jun 2015, registered Jul 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Hepatitis by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Hepatitis · Gilead Sciences.

Enrollment
11th of 23
181 · median 155
Started
2015
with 2 others
Phase 3
9 of 25
none open now
Registered
23rd of 25
by date

Among the 25 studies in Hepatitis by Gilead Sciences, this one is the 11th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2015, is one of 9 in phase 3, and was the 23rd registered.

Hepatitis

344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.

Browse Hepatitis studies →

Open to participants now

None of the 25 studies in Hepatitis by Gilead Sciences is open now. The open studies under Hepatitis, anywhere →

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Hepatitis by Gilead Sciences as a file.
02

Study summary

The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV) infection in China.

Read the detailed description

This study GS-US-320-0110 is an international study planned to enroll participants in global countries, including China. However, due to the review timeline difference in China, full enrollment was reached in the main study (NCT01940471) before China was able to participate. Therefore, this registration only includes the China cohorts as they were not part of the main study analysis. Data for China cohorts were analyzed separately after the main study analysis was completed.

03

Conditions studied

  • HBV
  • Chronic HBV Infection

Browse trials for

Keywords

  • Hepatitis
  • Tenofovir
  • Viread
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Ability to understand and sign a written form, which must be obtained prior to initiation of study procedures
  • Adult males and non-pregnant, non-lactating females
  • Documented evidence of chronic infection
  • HBeAg-positive, chronic hepatitis B with all of the following:

    • HBeAg-positive at screening
    • Screening HBV DNA ≥ 2 x 10\^4 IU/mL
    • Screening serum (ALT) level > 60 U/L (males) or > 38 U/L (females) and ≤ 10 x the (ULN)
  • Treatment-naive participants (defined as \< 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue) OR treatment-experienced participants (defined as participants meeting all entry criteria [including HBV DNA and serum ALT criteria] and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue)
  • Previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit
  • Adequate renal function
  • Normal

Key Exclusion Criteria:

  • Females who are breastfeeding
  • Males and females of who are unwilling to use an "effective", protocol specified method(s) of during the study
  • Co-infection with virus, , or hepatitis D virus
  • Evidence of hepatocellular carcinoma
  • Any history of, or current evidence of, clinical hepatic decompensation
  • Abnormal hematological and biochemical parameters, including aspartate aminotransferase (AST) > 10 x ULN
  • Received solid organ or bone marrow transplant
  • History of within the past 5 years, with the exception of specific cancers that are cured by surgical resection; individuals under evaluation for possible malignancy are not eligible
  • Currently receiving therapy with immunomodulators (eg, ), agents, nephrotoxic agents, or agents capable of modifying renal excretion
  • Individuals receiving ongoing therapy with drugs not to be used with tenofovir alafenamide or tenofovir disoproxil fumarate or individuals with a known to study drugs, metabolites, or formulation
  • Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance
  • Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Double-Blind TAF

    Tenofovir alafenamide (Vemlidy®; TAF) 25 mg tablet + tenofovir disoproxil fumarate (Viread®; TDF) placebo tablet once daily for up to 144 weeks (per amendment 3.1).

    Drug: TAF · Drug: TDF Placebo

  • Active comparator
    Double-Blind TDF

    TDF 300 mg tablet + TAF placebo tablet once daily for up to 144 weeks (per amendment 3.1).

    Drug: TDF · Drug: TAF Placebo

  • Experimental
    Open-label TAF

    All participants who complete the double-blind period will be eligible to receive open-label TAF until Week 384 of the study.

    Drug: TAF

Interventions

  • DrugTAF

    TAF 25 mg tablet administered orally once daily

    Also known as: GS-7340, Vemlidy®

  • DrugTDF

    TDF 300 mg tablet administered orally once daily

    Also known as: Viread®

  • DrugTAF Placebo

    TAF placebo tablet administered orally once daily

  • DrugTDF Placebo

    TDF placebo tablet administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 48

    Time frame: Week 48

  2. Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

    Time frame: Baseline; Week 48

  3. Percent Change From Baseline in Spine BMD at Week 48

    Time frame: Baseline; Week 48

  4. Change From Baseline at Week 48 in Serum Creatinine

    Time frame: Baseline; Week 48

Other outcomes

  1. Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48

    Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.

    Time frame: Up to 48 weeks

07

Results

Posted Apr 17, 2018

Participant flow

Participants were enrolled at study sites in China.

Double-Blind Treatment Phase
Participant flow — Double-Blind Treatment Phase
MilestoneDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mgOpen-label: TAF 25 mg to TAF 25 mgOpen-label: TDF 300 mg to TAF 25 mg
Started1235800
Completed1145200
Not completed9600
Withdrew: Randomized but never treated0100
Withdrew: Pregnancy3100
Withdrew: Withdrew consent5200
Withdrew: Lost to follow-up0100
Withdrew: Investigator's discretion0100
Withdrew: Non-compliance with study drug1000
Open-Label TAF Treatment Phase
Participant flow — Open-Label TAF Treatment Phase
MilestoneDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mgOpen-label: TAF 25 mg to TAF 25 mgOpen-label: TDF 300 mg to TAF 25 mg
Started0011352
Completed0010048
Not completed00134
Withdrew: Lost to follow-up0061
Withdrew: Withdrew consent0043
Withdrew: Death0010
Withdrew: Lack of efficacy0010
Withdrew: Pregnancy0010

Outcome measures

PrimaryPercentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48
Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48
percentage of participantsDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mg
Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 4861.068.4
SecondaryPercentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 48
Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 48
percentage of participantsDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mg
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion to Antibody Against Hepatitis B e Antigen (Anti-HBe) at Week 4811.08.8
SecondaryPercent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48
percent changeDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mg
Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 480.624 ± 2.2731-1.507 ± 2.4193
SecondaryPercent Change From Baseline in Spine BMD at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · percent change
Percent Change From Baseline in Spine BMD at Week 48
percent changeDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mg
Percent Change From Baseline in Spine BMD at Week 480.683 ± 3.3281-2.169 ± 3.4503
SecondaryChange From Baseline at Week 48 in Serum Creatinine
Time frame:
Baseline; Week 48
Reported as:
Mean · mg/dL
Change From Baseline at Week 48 in Serum Creatinine
mg/dLDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mg
Change From Baseline at Week 48 in Serum Creatinine-0.003 ± 0.07010.016 ± 0.0920
Other pre-specifiedPercentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.

Time frame:
Up to 48 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48
percentage of participantsDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mg
Grade 124.422.8
Grade 20.83.5
Grade 300

Adverse events

Collected over All-Cause Mortality: Up to approximately 414 weeks; Adverse Events: Up to Week 384. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind: TAF 25 mg0/123 (0%)8/123 (6.5%)85/123 (69.1%)
Double-Blind: TDF 300 mg0/57 (0%)3/57 (5.3%)43/57 (75.4%)
Open-label TAF Extension Phase: TAF 25 mg to TAF 25 mg1/113 (0.9%)7/113 (6.2%)84/113 (74.3%)
Open-label TAF Extension Phase: TDF 300 mg to TAF 25 mg0/52 (0%)4/52 (7.7%)42/52 (80.8%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mgOpen-label TAF Extension Phase: TAF 25 mg to TAF 25 mgOpen-label TAF Extension Phase: TDF 300 mg to TAF 25 mg
PyrexiaGeneral disorders0/1230/570/1131/52
AppendicitisInfections and infestations1/1230/570/1131/52
PneumoniaInfections and infestations0/1230/570/1131/52
Upper respiratory tract infectionInfections and infestations0/1230/570/1131/52
HyperglycaemiaMetabolism and nutrition disorders0/1230/570/1131/52
Appendix cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1230/570/1131/52
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1230/570/1131/52
Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1230/572/1131/52
Uterine polypReproductive system and breast disorders0/1230/570/1131/52
HaemorrhoidsGastrointestinal disorders0/1231/570/1130/52
Most frequent other events
Showing 10 of 29
Most frequent other events
EventDouble-Blind: TAF 25 mgDouble-Blind: TDF 300 mgOpen-label TAF Extension Phase: TAF 25 mg to TAF 25 mgOpen-label TAF Extension Phase: TDF 300 mg to TAF 25 mg
Covid-19Infections and infestations0/1230/5745/11312/52
Hepatic steatosisHepatobiliary disorders10/1233/5724/11318/52
NasopharyngitisInfections and infestations40/12312/5711/1136/52
Upper respiratory tract infectionInfections and infestations27/12316/5720/11312/52
Urinary tract infectionInfections and infestations8/1238/572/1132/52
HypertensionVascular disorders3/1231/577/1137/52
OsteopeniaMusculoskeletal and connective tissue disorders0/1235/576/1135/52
HyperlipidaemiaMetabolism and nutrition disorders6/1230/5710/1132/52
DiarrhoeaGastrointestinal disorders6/1233/579/1131/52
Hepatic cystHepatobiliary disorders5/1231/570/1134/52

Baseline characteristics

Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug. Participants were analyzed according to the treatment they actually received during the double-blinded phase.

Age, Categorical
Age, Categorical(Participants)Double-Blind: TAF 25 mgDouble-Blind: TDF 300 mgTotal
<=18 years202
Between 18 and 65 years12157178
>=65 years000
Age, Continuous
Age, Continuous(years)Double-Blind: TAF 25 mgDouble-Blind: TDF 300 mgTotal
Mean34 ± 9.436 ± 9.534 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind: TAF 25 mgDouble-Blind: TDF 300 mgTotal
Female351348
Male8844132
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind: TAF 25 mgDouble-Blind: TDF 300 mgTotal
Hispanic or Latino000
Not Hispanic or Latino12357180
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind: TAF 25 mgDouble-Blind: TDF 300 mgTotal
Asian12357180
HBV DNA
HBV DNA(log10 IU/mL)Double-Blind: TAF 25 mgDouble-Blind: TDF 300 mgTotal
Mean7.2 ± 1.657.2 ± 1.487.2 ± 1.59
Plasma HBV DNA Level
Plasma HBV DNA Level(Participants)Double-Blind: TAF 25 mgDouble-Blind: TDF 300 mgTotal
< 8 log10 IU/mL7436110
≥ 8 log10 IU/mL492170
IL28b Status
IL28b Status(Participants)Double-Blind: TAF 25 mgDouble-Blind: TDF 300 mgTotal
CC10952161
CT12517
TT202

2 further baseline measures are reported on the registry.

08

Study locations

25 sites
  • Beijing Ditan Hospital
    Beijing, 100015, China
  • PLA 302 Hospital
    Beijing, 100039, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, 100050, China
  • Beijing Youan Hospital, Capital Medical University
    Beijing, 100069, China
  • Xianya Hospital, Central South University
    Changsha, 410008, China
  • Guangzhou Eighth People's Hospital
    Guangzhou, 510060, China
  • Nanfang Medical University, Nanfang Hospital
    Guangzhou, 510515, China
  • No. 3 Hospital, Zhongshan Medical University
    Guangzhou, 510630, China
  • The Affiliated Hospital of Guiyang Medical College
    Guiyang, 550004, China
  • The People's Hospital of Hainan Province
    Haikou, 570311, China
  • The Second Xiangya Hospital of Central South University
    Hunan, 410011, China
  • The First Affiliated Hospital of Nanchang University
    Jiangxi, 330006, China
  • 1st Hospital Jilin University
    Jilin, 130021, China
  • Jinan Infectious Disease Hospital
    Jinan, 250021, China
  • 2nd Hospital of Nanjing City
    Nanjing, 210003, China
  • Jiangsu Province People's Hospital
    Nanjing, 210029, China
  • Ruijin Hospital, JiaoTong University School of Medicine
    Shanghai, 200025, China
  • Shanghai Public Health Clinical Center
    Shanghai, 200083, China
  • 85 Hospital of People's Liberation Army
    Shanghai, 200235, China
  • Shengjing Hospital of China Medical University
    Shenyang, 110004, China
  • The Sixth People's Hospital of Shenyang
    Shenyang, 110006, China
  • 3rd Hospital of Hebei Medical University
    Shijiazhuang, 050051, China
  • West China Hospital, Sichuan University
    Sichuan, 610041, China
  • First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, 710061, China
  • 1st Affiliated Hospital Kunming Medical College
    Yunnan, 650032, China
09

References and documents

Publications

  • Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Wang FS, Zhang L, Wu S, Tang H, Li J, Lin F, Yang Y, Gong G, Flaherty JF, Gaggar A, Mo S, Cheng C, Camus G, Chen C, Huang Y, Jia J, Zhang M; GS-US-320-0110 and GS-US-320-0108 China Investigators. 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China. J Clin Transl Hepatol. 2021 Jun 28;9(3):324-334. doi: 10.14218/JCTH.2020.00145. Epub 2021 Apr 28. PubMed 34221918 ↗
  • Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Zhang L, Wu S, Tang H, Li J, Lin F, Yang Y, Gong G, Luo Y, Xie S, Wang H, Mateo R, Yazdi T, Abramov F, Yee LJ, Flaherty J, Chen C, Huang Y, Zhang M, Jia J. Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients. J Clin Transl Hepatol. 2024 May 28;12(5):469-480. doi: 10.14218/JCTH.2023.00417. Epub 2024 Apr 15. PubMed 38779514 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gileadclinicaltrials.com/transparency-policy#Commitment

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gileadclinicaltrials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2015 to primary completion in Mar 2017, 21 months.

Results were first posted in Apr 2018, 1 year after primary completion.

Of 23 phase 3 interventional studies under Hepatitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2016
First posted
Jul 18, 2016
StartActual
Jun 19, 2015
Primary completionActual
Mar 21, 2017
CompletionActual
Aug 31, 2023
Results first posted
Apr 17, 2018
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02836249
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jul 18, 2016
Start date
Jun 19, 2015
Primary completion
Mar 21, 2017
Completion
Aug 31, 2023
Results posted
Apr 17, 2018
Last update
Oct 15, 2024

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir alafenamide

Start the discussion